Bio-Path Holdings, Inc., (Nasdaq: BPTH) announced that a review of BP1001 data as a treatment for chronic myelogenous leukemia (CML) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE